參考文獻(xiàn)/References:
[1] Hsieh J J, Purdue M P, Signoretti S, et al.Renal cell carcinoma[J]. Nature Reviews Disease Primers, 2017,3(3):17009.[2] Cho E, Adami Ho Fau- Lindblad P, Lindblad P.Epidemiology of renal cell cancer[J]. Hematol Oncol Clin North Am, 2011, 25(4): 651-665.[3] Sánchez-Gastaldo A, Kempf E, González Del Alba A, et al.Systemic treatment of renal cell cancer: a comprehensive review[J]. Cancer Treatment Reviews,2017(60): 77-89.[4] Mennitto A, Verzoni E, Grassi P, et al.Multimodal treatment of advanced renal cancer in 2017[J].Expert Rev Clin Pharmacol,2017, 10(12): 1395-1402.[5] Lin H, Chen Q L, Wang X Y, et al.Clinical significance of pituitary tumor transforming gene 1 and transgelin-2 in pancreatic cancer[J]. Int J Immunopathol Pharmacol,2013, 26(1):147-156.[6] 趙振威, 李延江.腎細(xì)胞癌流行病學(xué)的研究進(jìn)展[J]. 山東醫(yī)藥,2013, 53(7):95-97.[7] Saika T, Ono Y, Hattori R, et al.Long-term outcome of laparoscopic radical nephrectomy for pathologic T1 renal cell carcinoma[J]. Urology,2003, 62(6):1018-1023.[8] Motzer R J, Bander N H, Nanus D M.Renal-cell carcinoma[J]. N Engl J Med,1996, 335(12):865-875.[9] Cairns P.Renal cell carcinoma[J]. Cancer Biomark,2010, 9(1/6):461-473.[10] Zhang J, Yang Y, Chen L,et al.Overexpression of pituitary tumor transforming gene(PTTG)is associated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma[J]. Acta Histochem,2014, 116(3):435-439.[11] 魏先, 胡志全.轉(zhuǎn)移性腎細(xì)胞癌免疫治療進(jìn)展[J]. 現(xiàn)代泌尿生殖腫瘤雜志,2017, 9(1):1-4.[12] 郭常利.垂體腫瘤與相關(guān)基因的研究進(jìn)展[J]. 中國(guó)臨床神經(jīng)科學(xué),2002, 10(3):321-324.[13] Liao Y C, Ruan J W, Lua I, et al.Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling[J]. Oncogene,2012, 31(25):3086-3097.[14] Hamid T, Kakar S S.PTTG/securin activates expression of p53 and modulates its function[J]. Mol Cancer,2004,3(3):18.